14 million Americans suffer migraine headaches everyday. Many go untreated and many who are treated continue to have headaches. An old drug may offer a new way to treat migraines, with the FDA approval of botulinum toxin injections for severe chronic migraine. Dr. David Simpson, professor of neurology at Mount Sinai School of Medicine in New York City and director of the clinical neurophysiology lab at Mount Sinai Hospital, joins host Dr. Anthony Alessi to discuss what patients qualify for this treatment, problems and risks associated with taking the injections, and the controversial results of the clinical trials for this treatment, including the PREEMPT 1 and 2 trials.
Produced in cooperation with: